Market Strategy 2/10/2020
- February 10, 2020
Riders on the Storm Revisited
Investors’ focus this week is likely to be on the implications of the coronavirus on economies and markets worldwide.
Key Takeaways
- Our experience tells us that as disconcerting as the spread of the coronavirus has been to date, the global focus on the illness is likely to produce a solution to stem its spread before long.
- Last week’s rally in global equities points to investors beginning to place the coronavirus in context of previous outbreaks of other deadly viruses.
- Economic data released last week underscored strength and resilience in the US labor market and pointed toward the sustainability of the US economic expansion.
- With 64% of S&P 500 firms having reported results in the Q4 earnings season, 74% of those have reported positive earnings surprises.
As we prepared to go to press on Sunday evening the number of confirmed coronavirus cases in mainland China had risen to 40,171 with the death toll at 908 as of the end of February 9. Of the 908 deaths thus far reported, 871 have occurred in Hubei province where the outbreak of the virus has been sourced to. So far there have been two deaths reported outside of the Chinese mainland: one in the Philippines and one in Hong Kong.
As worrisome as the news of the virus’s spread is with its cost to humanity and to society, for investors the questions are: how long will it take for the coronavirus to peak?; how long will it take health care professionals to find a vaccine or medication to stem the spread of the virus?; and, what will be the cost to business, labor, communities and governments before a method to stem the spread of the virus is found?
Recent history and our experience tells us that SARs, Ebola and Zika were effectively dealt with in a much shorter time than was projected at outbreak and with less damage to the regional economies directly affected and to the broader world economy than was feared in the period before medical researchers and other professionals arrived at an effective methodology to stem those maladies’ spread and heal those affected.
We view last week’s global rally in stocks as a market response to the earlier sell-off that had occurred around January 17 when the virus was reported and began to make headlines. Since then improved economic data and so far a better than expected Q4 earnings season stateside along with a sense of context placing the current virus in relation to other viruses in modern times provided some lift to stocks and indeed even to yields with the ten-year treasury yield rising from 1.507% on January 31 to as high as 1.651% on February 6. As of Sunday evening the ten-year yield had slipped to 1.595%, reflective of markets in early morning trading in Asia acknowledging the latest coronavirus numbers.
Portfolio diversification shines in challenging times with some parts of the portfolio serving as ballast to weather the storm in its immediacy while other parts offer dry powder—positioning for opportunities that may surface… Riders on the Storm Revisited Investors’ focus this week is likely to be on the implications of the coronavirus on economies and markets worldwide. 1
Over the weekend a number of technology companies were reported to be canceling plans to attend the MWC Barcelona Trade Show (the world’s biggest trade show for the mobile telephony industry) which is scheduled at the end of February.
When the Rubber Meets the Road
In our view portfolio diversification shines in challenging times with some parts of the portfolio serving as ballast to weather the storm in its immediacy while other parts offer dry powder—positioning for opportunities that surface— while other parts remain forward-facing—looking ahead to when the current disturbance exits the landscape. With diversification sensitive to an individual’s or an institutional entity’s goals, objectives, and risk tolerances, the capability to “stay the course” can be significant and ultimately rewarding.
We persist overweight equities versus bonds (see our global asset allocation model on page 10 of this report for details) with an overweight in US equities while maintaining meaningful exposure to developed and emerging international market equities. We continue to favor cyclical sectors over defensives on expectations that central banks will remain sensitive to both strengths and vulnerabilities within their economies. We also anticipate that solutions may be found sooner than currently expected to stem the spread of the coronavirus and heal those suffering from the illness. We also believe the market has not yet fully priced in the benefits to be derived from the phase one agreement between the US and China as the year unfolds.
John Stoltzfus
Title:Chief Investment Strategist, Oppenheimer Asset Management Inc.
John is one of the most popular faces around Oppenheimer: our clients have come to rely on his market recaps for timely analysis and a confident viewpoint on the road forward. He frequently lends his expertise to CNBC, Bloomberg, Fox Business, and other notable networks.
Other Disclosures
This report is issued and approved by Oppenheimer & Co. Inc., a member of all Principal Exchanges, and SIPC. This report is distributed by Oppenheimer & Co. Inc., for informational purposes only, to its institutional and retail investor clients. This report does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited. The securities mentioned in this report may not be suitable for all types of investors. This report does not take into account the investment objectives, financial situation or specific needs of any particular client of Oppenheimer & Co. Inc. Recipients should consider this report as only a single factor in making an investment decision and should not rely solely on investment recommendations contained herein, if any, as a substitution for the exercise of independent judgment of the merits and risks of investments. The strategist writing this report is not a person or company with actual, implied or apparent authority to act on behalf of any issuer mentioned in the report. Before making an investment decision with respect to any security discussed in this report, the recipient should consider whether such investment is appropriate given the recipient's particular investment needs, objectives and financial circumstances. We recommend that investors independently evaluate particular investments and strategies, and encourage investors to seek the advice of a financial advisor. Oppenheimer & Co. Inc. will not treat non-client recipients as its clients solely by virtue of their receiving this report. Past performance is not a guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance of any security mentioned in this report. The price of the securities mentioned in this report and the income they produce may fluctuate and/or be adversely affected by exchange rates, and investors may realize losses on investments in such securities, including the loss of investment principal.
Oppenheimer & Co. Inc. accepts no liability for any loss arising from the use of information contained in this report. All information, opinions and statistical data contained in this report were obtained or derived from public sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such information, opinion or statistical data is accurate or complete and they should not be relied upon as such. All estimates and opinions expressed herein constitute judgments as of the date of this report and are subject to change without notice. Nothing in this report constitutes legal, accounting or tax advice. Since the levels and bases of taxation can change, any reference in this report to the impact of taxation.
Investment Strategy should not be construed as offering tax advice on the tax consequences of investments. As with any investment having potential tax implications, clients should consult with their own independent tax adviser.
This report may provide addresses of, or contain hyperlinks to, Internet web sites. Oppenheimer & Co. Inc. has not reviewed the linked Internet web site of any third party and takes no responsibility for the contents thereof. Each such address or hyperlink is provided solely for the recipient's convenience and information, and the content of linked third party web sites is not in any way incorporated into this document. Recipients who choose to access such third-party web sites or follow such hyperlinks do so at their own risk. The S&P 500 Index is an unmanaged value-weighted index of 500 common stocks that is generally considered representative of the U.S. stock market. The S&P 500 index figures do not reflect any fees, expenses or taxes. This research is distributed in the UK and elsewhere throughout Europe, as third party research by Oppenheimer Europe Ltd, which is authorized and regulated by the Financial Conduct Authority (FCA). This research is for information purposes only and is not to be construed as a solicitation or an offer to purchase or sell investments or related financial instruments. This report is for distribution only to persons who are eligible counterparties or professional clients and is exempt from the general restrictions in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the UK only to persons of a kind described in Article 19(5) (Investment Professionals) and 49(2) High Net Worth companies, unincorporated associations etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. In particular, this material is not for distribution to, and should not be relied upon by, retail clients, as defined under the rules of the FCA. Neither the FCA’s protection rules nor compensation scheme may be applied. This report or any portion hereof may not be reprinted, sold, or redistributed without the written consent of Oppenheimer & Co. Inc. Copyright © Oppenheimer & Co. Inc. 2019.